Cocrystal Discovery Receives Awards for Its Novel Antiviral Drug Development Programs

Cocrystal Discovery Announces Grants totaling $733,438

SEATTLE, Nov. 3, 2010 /PRNewswire/ -- Cocrystal Discovery, Inc., a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases, announced today that it has received $733,438 in grants from the Qualified Therapeutic Discovery Project (QTDP) administered under section 48D of the Internal Revenue Code.  The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer.

The QTDP grants awarded to Cocrystal are for programs in hepatitis C, influenza, and the common cold, diseases that collectively affect billions of people worldwide.

Cocrystal is a biopharmaceutical company dedicated to the development of small molecule, broad-spectrum antiviral therapeutics. The Company has laboratories in Bothell, Washington and Mountain View, California.  Cocrystal is a privately held company with headquarters in Bothell, Washington.  

SOURCE Cocrystal Discovery, Inc.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.